Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
17 participants
OBSERVATIONAL
2011-07-31
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The effect of the improved Reader performance is illustrated by plotting the ROC curves for XRM alone and XRM+ABUS. If Reader performance improves with the addition of ABUS to the XRM, the area under the curve (AUC) for XRM+ABUS (AUCXRM+ABUS) will be greater than the area under the curve for XRM Alone (AUCXRM Alone). This difference is represented as ∆AUCABUS. The null and alternative hypotheses can be formally expressed as follows:
H0: ∆AUCABUS = 0, AUCXRM+ABUS = AUCXRM Alone The null hypothesis is that Reader performance will be unchanged with the addition of ABUS to a screening mammogram assigned a BI-RADS Assessment Category of 1 or 2.
HA: ∆AUCABUS ≠ 0, AUCXRM+ABUS ≠ AUCXRM Alone The alternative hypothesis is that Reader performance will be changed with the addition of ABUS to a screening mammogram assigned a BI-RADS Assessment Category of 1 or 2. A statistically significant change will be considered equivalent to a statistically significant improvement if the estimated value of AUCXRM+ABUS is greater than that of AUCXRM Alone with statistical significance at an alpha level of .05 for a two-sided test.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
NCT00816530
Diagnostic Performance of an Automated Breast Ultrasound System (ABUS)
NCT02661204
Delphinus SoftVue™ ROC Reader Study (DMT SV RRS3)
NCT04260620
Automated Breast Ultrasound Screening
NCT02650778
Assessment of Automated Breast Ultrasound
NCT02386176
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Readers will review a total of 200 cases: the Non-Cancer Case Set, the Cancer Case Set, and additional Control and Supplemental Case Sets. These cases will be randomized during the reading session so each Reader will review the entire Case Set in a unique order.
The primary Receiver Operating Characteristic analysis will be performed on the Readers' Likelihood of Malignancy (LOM) ratings from their initial review of the screening mammogram alone and their final review of the screening mammogram and Automated Breast Ultrasound for the Non-Cancer Case Set and Cancer Case Set.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Asymptomatic Women who have Dense Breast Tissue
Women who have no signs or symptoms of breast cancer who have \> 50% parenchymal density on mammography.
Automated Breast Ultrasound (ABUS)
Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Automated Breast Ultrasound (ABUS)
Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fellowship-Trained in Breast Imaging and or have 10 years experience in breast imaging in which the radiologist's practice was at least 70% breast imaging
* Currently meets the minimum Mammography Interpretation requirements per MQSA
* Review Rate of at least 1,000 Mammograms annually for the year prior to study participation
* Review Rate of at least 500 Breast Ultrasounds annually for the year prior to study participation
* Successful completion of ABUS training
Exclusion Criteria
* Does not meet requirements of Fellowship-Trained in Breast Imaging and or have 10 years experience in breast imaging in which the radiologist's practice was at least 70% breast imaging
* Does not meet requirements of minimum Mammography Interpretation requirements per MQSA
* Does not meet requirements of Review Rate of at least 1,000 Mammograms annually for the year prior to study participation
* Does not meet requirements of Review Rate of at least 500 Breast Ultrasounds annually for the year prior to study participation
* Does not meet requirements of successful completion of ABUS training
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
U-Systems, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maryellen Giger, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Chicago, Department of Radiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
U-Systems, Inc.
Sunnyvale, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
USI2011001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.